Tim-3–expressing endothelium correlates with clinical features of lymphoma
| Features | Cases | Tim-3 | |||
| Scorea | t | p-value | |||
| Total lymphoma | |||||
| Gender | Male | 54 | 0.994 ± 0.677 | 0.842 | 0.402 |
| Female | 31 | 1.125 ± 0.721 | |||
| Age | ≤40 yr | 42 | 0.944 ± 0.71 | 1.289 | 0.201 |
| >40 yr | 43 | 1.137 ± 0.667 | |||
| Clinical stage | I+II | 42 | 0.889 ± 0.604 | 2.056 | 0.043 |
| III+IV | 43 | 1.191 ± 0.745 | |||
| A&B symptoms | A | 34 | 0.849 ± 0.688 | 2.136 | 0.037 |
| B | 51 | 1.17 ± 0.67 | |||
| Histology | B | 48 | 1.026 ± 0.705 | 0.359 | 0.72 |
| T | 37 | 1.081 ± 0.684 | |||
| IPI | <2 | 11 | 0.477 ± 0.529 | 3.646 | 0.002 |
| ≥2 | 74 | 1.125 ± 0.676 | |||
| B cell lymphoma | |||||
| Gender | Male | 32 | 1.017 ± 0.711 | 0.114 | 0.91 |
| Female | 16 | 1.042 ± 0.715 | |||
| Age | ≤40 yr | 23 | 0.967 ± 0.697 | 0.545 | 0.588 |
| >40 yr | 25 | 1.079 ± 0.722 | |||
| Clinical stage | I+II | 28 | 0.755 ± 0.585 | 3.412 | 0.002 |
| III+IV | 20 | 1.405 ± 0.695 | |||
| A&B symptoms | A | 27 | 0.814 ± 0.721 | 2.547 | 0.014 |
| B | 21 | 1.298 ± 0.594 | |||
| IPI | <2 | 11 | 0.477 ± 0.529 | 3.667 | 0.001 |
| ≥2 | 37 | 1.189 ± 0.672 | |||
| T cell lymphoma | |||||
| Gender | Male | 22 | 0.959 ± 0.638 | 1.083 | 0.288 |
| Female | 15 | 1.213 ± 0.741 | |||
| Age | ≤40 yr | 19 | 0.916 ± 0.745 | 1.363 | 0.182 |
| >40 yr | 18 | 1.217 ± 0.593 | |||
| Clinical stage | I+II | 14 | 1.157 ± 0.569 | 0.654 | 0.517 |
| III+IV | 23 | 1.004 ± 0.75 | |||
| A&B symptoms | A | 7 | 0.986 ± 0.573 | 0.373 | 0.716 |
| B | 30 | 1.08 ± 0.714 | |||
| IPI | <2 | 0 | |||
| ≥2 | 37 | 1.062 ± 0.683 | |||
| Features | Cases | Tim-3 | |||
| Scorea | t | p-value | |||
| Total lymphoma | |||||
| Gender | Male | 54 | 0.994 ± 0.677 | 0.842 | 0.402 |
| Female | 31 | 1.125 ± 0.721 | |||
| Age | ≤40 yr | 42 | 0.944 ± 0.71 | 1.289 | 0.201 |
| >40 yr | 43 | 1.137 ± 0.667 | |||
| Clinical stage | I+II | 42 | 0.889 ± 0.604 | 2.056 | 0.043 |
| III+IV | 43 | 1.191 ± 0.745 | |||
| A&B symptoms | A | 34 | 0.849 ± 0.688 | 2.136 | 0.037 |
| B | 51 | 1.17 ± 0.67 | |||
| Histology | B | 48 | 1.026 ± 0.705 | 0.359 | 0.72 |
| T | 37 | 1.081 ± 0.684 | |||
| IPI | <2 | 11 | 0.477 ± 0.529 | 3.646 | 0.002 |
| ≥2 | 74 | 1.125 ± 0.676 | |||
| B cell lymphoma | |||||
| Gender | Male | 32 | 1.017 ± 0.711 | 0.114 | 0.91 |
| Female | 16 | 1.042 ± 0.715 | |||
| Age | ≤40 yr | 23 | 0.967 ± 0.697 | 0.545 | 0.588 |
| >40 yr | 25 | 1.079 ± 0.722 | |||
| Clinical stage | I+II | 28 | 0.755 ± 0.585 | 3.412 | 0.002 |
| III+IV | 20 | 1.405 ± 0.695 | |||
| A&B symptoms | A | 27 | 0.814 ± 0.721 | 2.547 | 0.014 |
| B | 21 | 1.298 ± 0.594 | |||
| IPI | <2 | 11 | 0.477 ± 0.529 | 3.667 | 0.001 |
| ≥2 | 37 | 1.189 ± 0.672 | |||
| T cell lymphoma | |||||
| Gender | Male | 22 | 0.959 ± 0.638 | 1.083 | 0.288 |
| Female | 15 | 1.213 ± 0.741 | |||
| Age | ≤40 yr | 19 | 0.916 ± 0.745 | 1.363 | 0.182 |
| >40 yr | 18 | 1.217 ± 0.593 | |||
| Clinical stage | I+II | 14 | 1.157 ± 0.569 | 0.654 | 0.517 |
| III+IV | 23 | 1.004 ± 0.75 | |||
| A&B symptoms | A | 7 | 0.986 ± 0.573 | 0.373 | 0.716 |
| B | 30 | 1.08 ± 0.714 | |||
| IPI | <2 | 0 | |||
| ≥2 | 37 | 1.062 ± 0.683 | |||
Expression score (mean ± SE). The expression score represents the expression level of Tim-3 protein in endothelium as calculated by the immunoreactivity scoring system. Corresponding t values and p-values are displayed for each cross tabulation.